CapForce Inc. · OTC:CFOR

CapForce — OpGen — Technical Presentation (October 2016)

26 slides from CapForce's technical presentation, Oct 29, 2016

  1. Slide 1: Healthcare Antibiotic Resistance Prevalence—DC (HARP-DC)

    Healthcare Antibiotic Resistance Prevalence—DC (HARP-DC) Jacqueline Reuben, MHS Center for Policy, Planning and Evaluation District of Columbia Department of Health October 29, 2016

  2. Slide 2: Nothing to Disclose

    Nothing to Disclose

  3. Slide 3: CRE: A Growing Concern

    CRE: A Growing Concern • Common • Resistant • Deadly • Spreading 3

  4. Slide 4: Working Together is Vital!

    Working Together is Vital! 4 Source: http://www.cdc.gov/vitalsigns/stop-spread/

  5. Slide 5: Working Together is Vital for Washington D.C.!

    Working Together is Vital for Washington D.C.! • Metropolitan city that is not part of any state • 6th largest metropolitan statistical area in the U.S. with over 6 million residents • All healthcare facilities clustered within 61 square miles • Also receive patients from MD, VA and international vi

  6. Slide 6: You Can’t Manage What You Don’t Measure

    You Can’t Manage What You Don’t Measure Infected • Colonization among asymptomatic patients common • Identified and unidentified colonized patients serve as reservoir for transmission Colonized • Burden of CRE can only be determined through surveillance cultures • D.C. does not mandate CRE reporting

  7. Slide 7: Study Design and Methods

    f a oe DGH District of Columbia K | ®» @) DES Hospital Association OpGen Study Design and Methods

  8. Slide 8: Study Design

    Study Design • Study team: – D.C. Department of Health – D.C. Department of Forensic Science – Public Health Lab – District of Columbia Hospital Association – OpGen Laboratories • 16 participating healthcare facilities: – 8 short-term acute care (STAC) – 7 long-term care (LTC) • 2 long-term acute ca

  9. Slide 9: Study Design

    Study Design • Surveillance conducted over a 1 to 3 day interval for each facility between January 11, 2016 and April 14, 2016 • CDC 2015 CRE surveillance definition • Peri-anal swab samples collected by facility-based volunteers • Independent external review • Verbal consent obtained 9

  10. Slide 10: Study Design

    Study Design • Exclusion criteria: – Psych or ob-gyn patients, inability to consent, or clinically inappropriate • Patient based variables collected: – Age, sex, and zip code • Unit location variables grouped as: – Critical care, step-down units, wards, inpatient rehabilitation, and long-term care (

  11. Slide 11: CRE Detection

    CRE Detection Analyzed at OpGen laboratories 11

  12. Slide 12: HARP-DC Results

    District of Columbia Hospital Association HARP-DC Results 12

  13. Slide 13: HARP-DC Results Overview

    HARP-DC Results Overview n = 2,217 n = 1,504 n = 1,036 13 * = 6 tests not performed † = 8 tests not performed

  14. Slide 14: Results by Facility and Facility Type

    Results by Facility and Facility Type Patient Care Type CRE (%) Range (%) Inpatient Rehabilitation 0.0 -- Long Term Care 7.0 0.0-29.4 Short Term Acute Care 5.0 0.0-7.7 -- Critical Care 6.7 0.0-11.6 -- Step down 1.6 0.0-3.7 -- Ward 5.0 0.0-9.5 Total 5.2 0.0-29.4 14

  15. Slide 15: CRE Prevalence by Age Group

    CRE Prevalence by Age Group 9 8.0 8 7 Prevalence (% with CRE) 5.9 6 5.6 5 4 3 2.2 2 1.8 1 0 Age <20 20-39 40-59 60-79 over 79 n 55 88 285 442 137 15

  16. Slide 16: CRE Prevalence by Sex

    CRE Prevalence by Sex 8 7.1 7 Prevalence (% Resistance) 6 5 4 3.6 3 2 1 p=0.01 0 16 Female Male

  17. Slide 17: CRE Identification by Detection Method

    CRE Identification by Detection Method Carbapenemase Genes Total Organisms Identified by blaKPC blaNDM blaOXA 48 No Carbapenemase (% of total ID-AST Detected CRE) (culture only) Klebsiella pneumoniae 16 3 19 (35.8) Enterobacter cloacae 6 1 7 (13.2) Escherichia coli 1 3 4 (7.5) Serratia marcescens 1

  18. Slide 18: Distribution of Organisms

    Distribution of Organisms 18

  19. Slide 19: DNA Profiles by Facility

    DNA Profiles by Facility Arlington Langley Park Acuitas Lighthouse Profile Detected on One Ward 19

  20. Slide 20: HARP-DC Conclusions

    District of Columbia Hospital Association OpGen HARP-DC Conclusions 20

  21. Slide 21: Strengths

    Strengths • One of few studies to assess regional prevalence that aligns with CDC’s recommended collaborative approach – 4 facility types sampled • Used surveillance cultures rather than clinical cultures – All participating ward types sampled, rather than selecting expected high prevalence areas •

  22. Slide 22: Limitations

    Limitations • Limited risk factor analysis • Results de-identified • Verbal consent challenges • Selection of peri-anal site – Patient acceptability – Difficulty for patients who were obese, bed-bound, or in chair • Variability in acceptance rate across facilities 22

  23. Slide 23: Conclusions

    Conclusions • CRE is endemic in DC facilities, with an average prevalence of 5.2% and wide variation across facilities • Importance of surveillance validated by genotypic profile tending to identify possible CRE transmission within and between facilities • Inpatient healthcare facilities in DC succe

  24. Slide 24: Thank you!

    BRIDGEPOINT bg FP MedStar Georgetown HOSPITAL Children’s National University Hospital Medical Center, @ SIBLEY MEMORIAL auWwiye UMC __HosPii. Thank you! 5 Vg a JOHNS HOPKINS MEDICINE THE GEORGE WASHINGTON ee . UNIVERSITY MedStar Washington PROVIDENCE Hospital Center Bee Eee un 3 HOSPITAL e Universal

  25. Slide 25: Supplemental Slides

    Supplemental Slides

  26. Slide 26: Projected Impact of Coordinated Approach

    Projected Impact of Coordinated Approach Slayton, Rachel B., et al. "Vital signs: estimated effects of a coordinated approach for action to reduce antibiotic-resistant 26 infections in health care facilities—United States." MMWR. Morbidity and mortality weekly report 64.30 (2015): 826.

OpGen — Technical Presentation (October 2016) on 6ix